Search Clinical Trials
Parent Therapeutic Areas: Ophthalmology

Eye Disorders/Infections

California

Berkeley : Sutter East Bay Medical Foundation

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

La Jolla : Coastal Neurological Medical Group, Inc.

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Paramount : Center for Clinical Trials, LLC

Red, crusty, sticky and swollen?

Paramount : Center for Clinical Trials, LLC

Rojos, encostrados, pegajosos e hinchados?

Colorado

Aurora : University of Colorado - Denver

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Fort Collins : Advanced Neurosciences Research

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Florida

Miami : Bascom Palmer Eye Institute

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Pompano Beach : Neurological Associates

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

St. Petersburg : Suncoast Neuroscience Associates

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Tallahassee : Neuro-Ophthalmology and Balance Disorders Clinic

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Georgia

Atlanta : Emory University School of Medicine; Neuro-Ophthalmology - Emory Eye Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Illinois

Glenview : Eye Care Ltd.

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Peoria : OSF Saint Francis Medical Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Kansas

Prairie Village : KU Eye Clinic, Dept. of Ophthalmology

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Louisiana

Shreveport : Research Solutions, LA

Research study for children and adults with symptoms of pink eye

Maryland

Baltimore : Johns Hopkins School of Medicine

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Baltimore : Maryland Center for MS

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Michigan

Grand Rapids : Saint Mary's Health Care

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Minnesota

Golden Valley : Minneapolis Clinic of Neurology, Ltd.

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Minneapolis : University of Minnesota

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Missouri

St. Louis : West County MS Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Montana

Missoula : Rocky Mountain Eye Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

New Jersey

New Brunswick : Robert Wood Johnson Medical School

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Newark : The Institute of Ophthalmology & Visual Science

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

New York

Albany : Upstate Clinic Research

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Buffalo : University of Buffalo-Buffalo General Hospital-Jacobs Neurological Institute

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

New York : Biomedical Research Alliance of New York

Dry Eye Disease - Adults

New York : Roosevelt Hospital

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Rochester : University of Rochester Medical Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Syracuse : SUNY Medical University

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

North Carolina

Charlotte : Neuroscience & Spine Institute, MS Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Durham : Duke University Eye Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Oklahoma

Oklahoma City : MS Center of Oklahoma

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Pennsylvania

Philadelphia : Philadelphia Eye Associates

Dry Eye Disease-Adults

Philadelphia : Philadelphia Eye Associates

Eye infection: Itchy eyelid, foreign body sensation, ocular dryness, burning or pain, and swollen or heavy eyelids?

Philadelphia : Neuro-Ophthalmologic Associates, P.C. - Wills Eye Institute

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Texas

Houston : University Eye Institute

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Utah

Salt Lake City : Lifetree Clinical Research

Have you been diagnosed with dry age-related macular degeneration (AMD)?

Salt Lake City : University of Utah, John Moran Eye Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Virginia

Charlottesville : University of Virginia

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Richmond : Virginia Commonwealth University/Medical College of Virginia

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Washington

Seattle : Neuro-Ophthalmic Consultants NW

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.

Wisconsin

Milwaukee : Aurora - St. Luke's Medical Center

The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.